Graph by PSI (available in public domain).

Some of the packaging errors on counterfeit drugs are quite comical.

The drug safety problem must be seen as a systemic failure. It is unfair to blame clinicians for serious ADR s, particularly in the absence of complete safety information.

The drug safety problem must be seen as a systemic failure.

These sudden changes regarding drug regulations have sparked heated discussions online.

For there are practical reasons to preserve biodiversity, and they apply to parasites just as much as to their hosts. Many of the most effective drugs, for example, were originally discovered in plants or animals.

The pharmaceutical industry, fueled by our desire for quick fixes, has effectively deployed its considerable power to promulgate the notion of disorders and illnesses in all domains of our lives.

Many of the most effective drugs, for example, were originally discovered in plants or animals.

The fundamental purpose of drug companies is to produce profits for shareholders.

Today, information provided by drug makers largely predominates over independent information.

Consider that apathy, excessive shopping, and overuse of the Internet are all serious contenders for inclusion in the next edition of the DSM, due to appear in 2012.

If the history of psychiatry is any guide, a new class of medication will soon be touted to treat them.

New drugs, which have been designed to inhibit tumor angiogenesis, are showing promise in clinical trials.

Malaria can be controlled through newly designed long lasting mosquito nets and a new generation of effective medicines. Other tropical diseases also can be controlled, and practical technologies for safe drinking water can dramatically reduce diarrheal diseases.

Malaria can be controlled through newly designed long lasting mosquito nets and a new generation of effective medicines.

Remarkable as it seems, only a small fraction of drugs are innovative in any meaningful sense of the word.

It is also rich in traditional knowledge, especially knowledge associated with indigenous and medicinal plants.

In China, fewer than 200 people work at the Center for Drug Evaluation, the agency that reviews applications for new drugs.

A decade ago, Japan s drug approval process was lethargic relative to that of other developed economies.

For example, the concept of pre hypertension could extend the use of anti hypertensive drugs dramatically, because everybody s blood pressure rises with age.

In China, for example, the manufacturers of pharmaceutical ingredients can dodge drug regulation by claiming that their products will be used for non medical purposes.

Previously, drug safety monitoring relied on occasional adverse reports from health professionals about patients' reaction to medicines. But this crisis revealed these reports' fundamental inadequacies, such that users' experiences with drugs can never credibly be ignored again.

Inherent to drug safety is the fact that all drugs, in addition to their benefits, cause harm in certain patients. Drug approval and use requires a careful weighing of desirable and undesirable effects.

Inherent to drug safety is the fact that all drugs, in addition to their benefits, cause harm in certain patients.

(ii) Expanding access to treatment, in a progressive and sustainable manner, including the prevention and treatment of opportunistic diseases and the effective use of antiretroviral medication

The opportunity stems from the fact that our doctors and nurses, our pharmacists and drug researchers, our biologists and biochemists are learning to do wonderful things. Many of these things are, and will be, expensive.

Here was the foot in the door, the first step toward conceptualizing strategies of research and then delivery of drugs to populations that are defined by ethnicity and race.

My company, for example, is launching a portfolio of 15 essential medicines to treat diseases including diabetes, respiratory illnesses, and breast cancer.

The opportunity stems from the fact that our doctors and nurses, our pharmacists and drug researchers, our biologists and biochemists are learning to do wonderful things.

For example, American, European, Japanese, and other drug regulators have developed guidelines, through the International Conference on Harmonization, that take advantage of their collective expertise.

The US Orphan Drug Act gives special status to a drug or biological product to treat a rare disease or condition upon the request of a sponsor.

An aid cutoff to Ethiopia would nonetheless lead to a lot of death among impoverished people, who will lack medicines, improved seeds, and fertilizer.

Because supplies of donated medicines can be unpredictable, they can create chaos in the market by preventing accurate quantification of needs and thus affecting planning.

Essential medicines and materials are in short supply water purification tablets, chlorine disinfectant, antibiotics, jerry cans, soap, water cisterns, and construction material for latrines.

If the conditions for drug approval and marketing become more severe, pharmaceutical companies will be forced to produce fewer me too drugs and more products of clinical importance. Requiring longer testing periods, and possibly extra resources, could be compensated by new drugs greater longevity on the market, and patent coverage could be extended.

Third, better conditions for the approval of new drugs should be matched by better use of drugs, which requires better information for prescribers.

Requiring longer testing periods, and possibly extra resources, could be compensated by new drugs greater longevity on the market, and patent coverage could be extended.

A partnership between governments, non profit research institutions, charities and pharmaceutical companies might be one way to clean up the approval process for new drugs.

Despite the innovation mentioned earlier, detecting counterfeit drugs is still a very difficult task and requires both advanced technology and the capacity to strictly enforce international regulations.

Those who defend such widespread use of prescription drugs insist that a significant part of the population is under treated and, by inference, under medicated.

UNITAID s patent pool for AIDS medicines, for example, allows generics producers to make cheaper versions of patented medicines by enabling patent holders to license their technology in exchange for royalties. Ultimately, generics remain the current front runner in terms of delivering affordable medicines.

By contrast, the United States Food and Drug Administration employs 4,000 reviewers, and the European Medicines Agency has 3,000.

UNITAID s patent pool for AIDS medicines, for example, allows generics producers to make cheaper versions of patented medicines by enabling patent holders to license their technology in exchange for royalties.

Although the Merck project successfully raised money for Costa Rican biodiversity research, few if any drugs have been developed, and the model has not been transferred elsewhere.

Predictably, China s approval process for new drugs is one of the world s slowest eight years on average.